Global Blood Therapeutics, Inc.
GBTDelisted Oct 5, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Global Blood Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 203 | 2 | 195 | −6 |
| Shares | 70.6M | 104.2K | 71.5M | +1.03M (+1.5%) |
| Value | $2.44B | $3.61M | $2.29B | −$152.5M (−6.3%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (27)
Institutions that held Global Blood Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (33)
Institutions that held Global Blood Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (2)
Institutions that held Global Blood Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 94,062 | $3.26M |
| Amalgamated Financial Corp. | 10,100 | $350.0K |